The macroeconomic burden of noncommunicable diseases and mental health conditions in South America.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 11 06 2023
accepted: 05 10 2023
medline: 1 11 2023
pubmed: 20 10 2023
entrez: 20 10 2023
Statut: epublish

Résumé

Noncommunicable diseases and mental health conditions (referred to collectively as NMHs) are the greatest cause of preventable death, illness, and disability in South America and negatively affect countries' economic performance through their detrimental impacts on labor supply and capital investments. Sound, evidence-based policy-making requires a deep understanding of the macroeconomic costs of NMHs and of their distribution across countries and diseases. The paper estimates and projects the macroeconomic burden of NMHs over the period 2020-2050 in 10 South American countries. We estimate the impact of NMHs on gross domestic product (GDP) through a human capital-augmented production function approach, accounting for mortality and morbidity effects of NMHs on labor supply, for the impact of treatment costs on physical capital accumulation, and for variations in human capital by age. Our central estimates suggest that the overall burden of NMHs in these countries amounts to $7.3 trillion (2022 international $, 3% discount rate, 95% confidence interval: $6.8-$7.8 trillion). Overall, the macroeconomic burden of NMHs is around 4% of total GDP over 2020-2050, with little variation across countries (from 3.2% in Peru to 4.5% in Brazil). In other words, without NMHs, annual GDP over 2020-2050 would be about 4% larger. In most countries, the largest macroeconomic burden is associated with cancers. Results from the paper point to a significant macroeconomic burden of NMHs in South America and provide a strong justification for investment in NMH prevention, early detection, treatment, and formal and informal care.

Identifiants

pubmed: 37862345
doi: 10.1371/journal.pone.0293144
pii: PONE-D-23-18152
pmc: PMC10588886
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0293144

Informations de copyright

Copyright: © 2023 Ferranna et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Health Aff (Millwood). 2019 Nov;38(11):1832-1839
pubmed: 31682483
JAMA. 2020 Mar 3;323(9):863-884
pubmed: 32125402
BMJ Glob Health. 2020 Feb 11;5(2):e002040
pubmed: 32133191
Lancet Planet Health. 2019 Sep;3(9):e390-e398
pubmed: 31538624
EClinicalMedicine. 2022 Jul 22;51:101580
pubmed: 35898316
Am J Public Health. 2021 Jun;111(6):1049-1054
pubmed: 33856880
PLoS One. 2020 Jul 23;15(7):e0236068
pubmed: 32702003
Lancet. 2007 Dec 8;370(9603):1929-38
pubmed: 18063029
Health Aff (Millwood). 2015 Sep;34(9):1464-71
pubmed: 26355047
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Cancer Epidemiol. 2018 Apr;53:27-34
pubmed: 29353153
Lancet. 2016 Sep 24;388(10051):1311-24
pubmed: 27475266
Value Health. 2018 Feb;21(2):131-139
pubmed: 29477390
Health Econ. 2014 May;23(5):516-28
pubmed: 23649673
Sci Transl Med. 2018 May 16;10(441):
pubmed: 29769285
JAMA Oncol. 2023 Apr 1;9(4):465-472
pubmed: 36821107
Lancet Public Health. 2022 Oct;7(10):e834-e843
pubmed: 36182233
J Benefit Cost Anal. 2019;10(Suppl 1):1-14
pubmed: 33282627
J Health Econ. 2010 May;29(3):333-46
pubmed: 20363520
Am J Nurs. 2008 Sep;108(9 Suppl):23-7; quiz 27
pubmed: 18797217
Health Econ. 2010 Dec;19(12):1478-96
pubmed: 19998332
Health Policy Open. 2022 Jul 16;3:100073
pubmed: 37383583
Bull World Health Organ. 2003;81(1):19-27
pubmed: 12640472
PLoS One. 2018 Nov 1;13(11):e0206702
pubmed: 30383802
Rev Panam Salud Publica. 2018 Feb 28;42:e18
pubmed: 31093047

Auteurs

Maddalena Ferranna (M)

Department of Pharmaceutical and Health Economics, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, United States of America.
Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, United States of America.

Daniel Cadarette (D)

Harvard Kennedy School, Cambridge, Massachusetts, United States of America.

Simiao Chen (S)

Heidelberg Institute of Global Health, Faculty of Medicine and University Hospital, Heidelberg University, Heidelberg, Germany.

Parastou Ghazi (P)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Faith Ross (F)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Leo Zucker (L)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

David E Bloom (DE)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH